跳至主要内容
临床试验/NCT06981481
NCT06981481招募中不适用

Post-marketing Clinical Monitoring of Safety and Performance of the Silimed® Brand Breast Tissue Expander for Breast Reconstruction

Silimed Industria de Implantes Ltda3 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2025年8月6日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
152
试验地点
3
主要终点
Adverse events

研究概览

简要总结

The study investigates the safety and performance of Silimed® brand breast tissue expander in women born with indication for breast reconstruction. The safety of the breast tissue expander will be evaluated by estimating known and unexpected adverse event rates through patient reports of adverse events after implantation. The performance of using Silimed® brand breast tissue expander will be evaluated by evaluating the assessment of tissue quality and satisfaction by the evaluating physician after implantation.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • provide written informed consent
  • female sex at birth;
  • be 18 years of age or older;
  • have an indication for reconstruction with breast expander + breast implant(s);
  • have a plan to receive an expander with a textured surface from the Silimed® brand + implant breast with textured surface from the Silimed® brand;
  • ability to comply with the protocol throughout the follow-up period.

排除标准

  • breast augmentation without reconstruction in at least one breast;
  • neoplasia of any type (except breast neoplasia), not yet treated or under treatment, or requiring surgical removal at the time of implantation;
  • pregnancy or breastfeeding at the time of implantation;
  • smoking, uncontrolled diabetes, obesity (from grade 2) and ASA III/IV;
  • active infection not yet treated or being treated at any site at the time of implantation;
  • report or record of adverse reactions or intolerance to silicone prior to implantation;
  • immune diseases that affect connective tissue in activity or under treatment (e.g. lupus erythematosus, discoid lupus, scleroderma, etc.) at the time of implantation;
  • record or report of use of illicit drugs or medications that increase the risk of immediate post-surgical complications (eg, medications that interfere with coagulation);
  • high surgical risk or complications in the immediate post-surgery period, estimated before the implantation;
  • evidence or report of tissue characteristics that are clinically inconsistent with a successful implantation (eg tissues with excessive fibrosis or compromised vascularization);
  • may not have participated in another clinical study up to 6 months before placement of the expander, unless the researcher deems it to be good for the participant and not impact the study;
  • previous treatment with radiotherapy;
  • any other condition that, based on the opinion of the researcher or designee, may prevent the provision of informed consent, make study participation unsafe, compromise adherence to the protocol, complicate the interpretation of study outcome data or otherwise interfere with the achievement of the study objectives.

研究组 & 干预措施

Women undergoing breast reconstruction with Silimed® breast tissue expander.

Women undergoing breast reconstruction with Silimed® brand breast tissue expander since the elegibility criterea was attended.

干预措施: Breast tissue expander (Device)

结局指标

主要结局

Adverse events

时间窗: Through study completion, an average of 1 year

Estimate adverse events rate for breast tissue expander

Evaluator's Satisfaction in Relation to expansion

时间窗: Through study completion, an average of 1 year

Estimate the performance of Silimed® brand breast tissue expander with through the satisfaction of the evaluator (investigator) regarding the result of the expansion so far. The assessment will be done by means of a likert scale, where the following satisfaction options can be selected: 1 = definitely unsatisfied, 2 = unsatisfied, 3 = slightly satisfied, 4 = satisfied and 5 = definitely satisfied.

Evaluator's Assessment of tissue quality

时间窗: Through study completion, an average of 1 year

The assessment of tissue quality is clinical and will occur at every visit, including the final assessment. Estimate the performance of Silimed® brand breast tissue expander with textured surface throught the satisfaction of the evaluator regarding the vascularization, innervation, color and texture of and quality of the expanded tissue. To measure satisfaction, a Likert scale where the following satisfaction options can be marked: 1 = definitely dissatisfied, 2 = dissatisfied, 3 = somewhat satisfied, 4 = satisfied and 5 = definitely satisfied. Satisfaction will be measured in percentages of each category of the Likert scale in each follow-up time. Values from 0 to 20 will be considered poor results, bad results from 21 to 40, intermediate results from 41 to 60, good results from 61 to 80, and excellent results from 81 to 100.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验